Aptamer-based discovery of MARK2 as a potential biomarker for targeted imaging and exosome detection of metastatic colorectal cancer.
Metastatic colorectal cancer (CRC) has a high recurrence rate, rapid progression and poor prognosis. Therefore, the discovery of metastatic related biomarkers is crucial for early diagnosis and treatment. Aptamer W14 was previously developed through cell-systematic evolution of ligands by exponential enrichment (SELEX)...